Thinking of joining a study?

Register your interest

NCT02335957 | COMPLETED | Breast Cancer


OPTimizing Irradiation Through Molecular Assessment of Lymph Node (OPTIMAL)
Sponsor:

Clinical Research Group in Radiotherapy Oncology

Information provided by (Responsible Party):

Esther Prats

Brief Summary:

The main purpose of this study is to show the non-inferiority of the incidental irradiation, as compared to intentional irradiation of the axillary nodes, in terms of 5-years disease-free survival (DFS) of early stage breast cancer patients with limited affectation of sentinel node assessed by OSNA (250 to 15,000 copies/uL), treated with breast-conservative surgery without axillary lymphadenectomy.

Condition or disease

Breast Cancer

Intervention/treatment

Irradiation

Phase

NA

Detailed Description:

Since long, the standard loco-regional treatment of the early-stage breast cancer is breast conservative surgery (tumorectomy) followed by a selective biopsy of the sentinel lymph node and, if positive, lymphadenectomy of axillary levels I and II. Complementary irradiation of the breast and ganglionar areas has shown to reduce disease-specific mortality. Therefore, adjuvant radiotherapy of the whole breast is currently indicated after conservative surgery. The recommendation to irradiate axillary lymph nodes is clear in patients with more than three affected nodes. The standard volumes to irradiate after lymphadenectomy include supraclavicular and level III axillary regions, while axillary levels I and II, and the internal breast lymph node chain, are reserved for cases of cumbersome axillary affectation, patients who have not undergone lymphadenectomy or it was insufficient, or affectation of the internal breast lymph node chain. However, when only 1 to 3 nodes are affected, there is no unanimity on the recommendation of radiotherapy, despite some studies have shown that irradiation improves survival. In addition, the National Cancer Institute of Canada trial (NCIC-CTGMA20), high risk patients with negative lymph nodes and patients with positive lymph nodes (most of them with 1 to 3 affected nodes) showed that local irradiation with or without regional lymph node irradiation improved disease-free survival, as well as loco-regional and distant disease control. Moreover, a systematic review including more than 20,000 patients from 45 studies concludes that the irradiation of the breast reduced the loco-regional relapse, even in patients without affected lymph nodes. One Step Nucleic Acid Amplification (OSNA) is a technique developed by Sysmex Corporation that allows a readily and complete analysis of sentinel lymph nodes during surgery. OSNA provides a quantification of the Cytokeratin 19 (CK19) tumour cell marker in the messenger ribonucleic acid (mRNA) of the sentinel node, the result being expressed as "total tumour load" (TTL), which is a discrete number of copies per microliter. This technique has shown ability to discriminate macrometastasis, micrometastasis or negativity, and to predict affectation of non-sentinel lymph nodes. According to previous results, a TTL \< 15,000 is associated with a 85% probability of non-affectation of (non-sentinel) axillar lymph nodes. The therapeutic value of the axillary lymphadenectomy has been questioned since long, and the recent publication of the Z0011 study proposes solely a selective biopsy of the sentinel lymph node. This has impacted clinical practice guidelines as prestigious as those of the National Comprehensive Cancer Network; however, irradiation is always considered in these cases. In summary, the amount of nodal volumes to irradiate in early stages of breast cancer is under discussion, particularly in the case of patients not submitted to axillar lymphadenectomy despite affectation of sentinel lymph nodes. In most cases, the irradiation of the breast implies "incidental" irradiation of the axillary level I, and in some cases the level II. For this reason, some groups have decided not to irradiate these axillary regions intentionally, while others advocate irradiating these regions intentionally.

Study Type : INTERVENTIONAL
Estimated Enrollment : 489 participants
Masking : NONE
Primary Purpose : TREATMENT
Official Title : OPTimizing Irradiation Through Molecular Assessment of Lymph Node (OPTIMAL)
Actual Study Start Date : 2015-04
Estimated Primary Completion Date : 2021-07
Estimated Study Completion Date : 2021-07

Information not available for Arms and Intervention/treatment

Ages Eligible for Study: 18 Years
Sexes Eligible for Study: FEMALE
Accepts Healthy Volunteers:
Criteria
Inclusion Criteria
  • 1. Infiltrating, ductal carcinoma of the breast.
  • 2. Treated with conservative surgery (tumorectomy or quadrantectomy) without lymphadenectomy.
  • 3. Sentinel lymph node assessed by OSNA, with TTL in the range 250 - 15,000 copies/μL.
  • 4. Age ≥ 18 yrs old.
  • 5. Karnofsky Index ≥ 70 %.
  • 6. Signed Informed Consent.
Exclusion Criteria
  • 1. Other types of breast cancer different from infiltrating ductal carcinoma.
  • 2. Bilateral breast cancer.
  • 3. Males.
  • 4. Mastectomy or axillary homolateral lymph node dissection.
  • 5. Previous thoracic irradiation therapy.
  • 6. Systemic neoadjuvant therapy previous to surgery.
  • 7. Contraindications of radiotherapy (pregnancy, severe collagen diseases).
  • 8. Other neoplasms.
  • 9. Severe associated comorbidities that, according to the investigator criteria, may interfere with the study evaluations.

OPTimizing Irradiation Through Molecular Assessment of Lymph Node (OPTIMAL)

Location Details

NCT02335957


Please Choose a site



How to Participate

Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.

Locations


Not yet recruiting

Italy,

Perugia Hospital

Perugia, Italy,

Not yet recruiting

Portugal,

São João Hospital Center

Porto, Portugal,

Not yet recruiting

Portugal,

Santarém District Hospital

Santarém, Portugal,

Not yet recruiting

Portugal,

Holy Spirit Hospital

Évora, Portugal,

Not yet recruiting

Spain, Asturias

Jove Hospital Foundation

Gijon, Asturias, Spain,

Not yet recruiting

Spain, Bilbao

Cruces Hospital

Barakaldo, Bilbao, Spain,

Not yet recruiting

Spain, Canary Islands

Gran Canaria University Hospital Dr. Negrín

Palms of Gran Canaria, Canary Islands, Spain,

Not yet recruiting

Spain, Madrid

Fuenlabrada University Hospital Complex

Fuenlabrada, Madrid, Spain,

Not yet recruiting

Spain, Madrid

Puerta de Hierro University Hospital

Majadahonda, Madrid, Spain,

Not yet recruiting

Spain, Murcia

Santa Lucia University General Hospital

Cartagena, Murcia, Spain,

Not yet recruiting

Spain, Navarra

Navarra Hospital Complex

Pamplona, Navarra, Spain,

Not yet recruiting

Spain,

Galicia Oncological Center

A Coruña, Spain,

Not yet recruiting

Spain,

Albacete University Hospital Complex

Albacete, Spain,

Not yet recruiting

Spain,

Ribera University Hospital

Alzira, Spain,

Not yet recruiting

Spain,

Infanta Cristina University Hospital

Badajoz, Spain,

Not yet recruiting

Spain,

Teknon Medical Center

Barcelona, Spain,

Not yet recruiting

Spain,

Platon Clinic

Barcelona, Spain,

Not yet recruiting

Spain,

Clinical Hospital of Barcelona

Barcelona, Spain,

Not yet recruiting

Spain,

Sea Hospital

Barcelona, Spain,

Not yet recruiting

Spain,

ICO Duran and Reynals

Barcelona, Spain,

Not yet recruiting

Spain,

Burgos University Hospital

Burgos, Spain,

Not yet recruiting

Spain,

Puerta del Mar University Hospital

Cadiz, Spain,

Not yet recruiting

Spain,

Provincial Hospital of Castellón

Castellón, Spain,

Not yet recruiting

Spain,

General University Hospital of Ciudad Real

Royal City, Spain,

Not yet recruiting

Spain,

Donostia Hospital

Donostia, Spain,

Not yet recruiting

Spain,

Virgen de las Nieves University Hospital

Granada, Spain,

Not yet recruiting

Spain,

Arnau de Vilanova University Hospital

Lerida, Spain,

Not yet recruiting

Spain,

University Hospital of León

León, Spain,

Not yet recruiting

Spain,

San Carlos University Clinical Hospital

Madrid, Spain,

Not yet recruiting

Spain,

Jiménez Díaz Foundation Hospital

Madrid, Spain,

Not yet recruiting

Spain,

Ramon y Cajal Hospital

Madrid, Spain,

Not yet recruiting

Spain,

12 de Octubre University Hospital

Madrid, Spain,

Not yet recruiting

Spain,

Gregorio Marañón University Hospital

Madrid, Spain,

Not yet recruiting

Spain,

La Paz University Hospital

Madrid, Spain,

Not yet recruiting

Spain,

Virgen de la Arrixaca General University Hospital

Murcia, Spain,

Not yet recruiting

Spain,

Sant Joan de Reus University Hospital

Reus, Spain,

Not yet recruiting

Spain,

University Hospital of Salamanca

Salamanca, Spain,

Not yet recruiting

Spain,

Santiago University Clinical Hospital

Santiago de Compostela, Spain,

Not yet recruiting

Spain,

Virgen de la Macarena Hospital

Sevilla, Spain,

Not yet recruiting

Spain,

Virgen del Rocío Hospital

Sevilla, Spain,

Not yet recruiting

Spain,

Valencia University Clinical Hospital

Valencia, Spain,

Not yet recruiting

Spain,

General University Hospital of Valencia

Valencia, Spain,

Not yet recruiting

Spain,

La Fe University and Polytechnic Hospital

Valencia, Spain,

Not yet recruiting

Spain,

Valencian Institute of Oncology (IVO)

Valencia, Spain,

Not yet recruiting

Spain,

University Clinical Hospital of Valladolid

Valladolid, Spain,

Not yet recruiting

Spain,

Vigo University Hospital Complex

Vigo, Spain,

Not yet recruiting

Spain,

Araba University Hospital

Vitoria, Spain,

Not yet recruiting

Spain,

Virgen de la Concha Hospital

Zamora, Spain,

Not yet recruiting

Spain,

Lozano Blesa University Clinical Hospital

Zaragoza, Spain,

Not yet recruiting

Spain,

Miguel Servet University Hospital

Zaragoza, Spain,

Loading...